Advertisement

Drugs & Therapy Perspectives

, Volume 35, Issue 4, pp 151–159 | Cite as

Encorafenib + binimetinib: a profile of their combined use in treating BRAF-mutated unresectable or metastatic melanoma

  • Katherine A. Lyseng-WilliamsonEmail author
Adis Drug Q&A
  • 28 Downloads

Abstract

Treatment with oral encorafenib (Braftovi®; a BRAF inhibitor) + binimetinib (Mektovi®; a MEK inhibitor) is a valuable addition to the options available to treat BRAF-mutated unresectable or metastatic melanoma in adults. The combination of encorafenib + binimetinib provided meaningful improvement with regard to progression-free survival, overall survival, clinical response and health-related quality of life relative to encorafenib and vemurafenib monotherapy in this patient population. The addition of binimetinib to encorafenib contributes to improving the efficacy and safety relative to encorafenib alone. Adverse events associated with encorafenib + binimetinib are manageable, with an overall tolerability profile largely consistent with those of other BRAF-MEK inhibitor combinations, but with some potential advantages with regard to pyrexia and photosensitivity. Adverse events that occur during encorafenib + binimetinib treatment can be managed with treatment adjustments.

Notes

Acknowledgements

The manuscript was reviewed by: G. Liszkay, Department of Oncodermatology, National Institute of Oncology, Budapest, Hungary, C. Robert, Département de Médecine Oncologique, Institute Gustave Roussy and Université Paris-Saclay, Villejuif, France; F. Vilchez-Márquez, Department of Dermatology, Hospital de Guadix, Guadix, Spain. During the peer review process, Pierre Fabre Médicament and Array BioPharma Inc., marketing-authorization holders of encorafenib and binimetinib, were also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with ethical standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

K. A. Lyseng-Williamson is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

References

  1. 1.
    Malissen N, Grob JJ. Metastatic melanoma: recent therapeutic progress and future. Drugs. 2018;78(12):1197–209.CrossRefGoogle Scholar
  2. 2.
    Kuske M, Westphal D, Wehner R, et al. Immunomodulatory effects of BRAF and MEK inhibitors: implications for melanoma therapy. Pharmacol Res. 2018;136:151–9.CrossRefGoogle Scholar
  3. 3.
    Network Cancer Genome Atlas. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–96.CrossRefGoogle Scholar
  4. 4.
    Adelmann CH, Ching G, Du L, et al. Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity. Oncotarget. 2016;7(21):30453–60.CrossRefGoogle Scholar
  5. 5.
    Kakadia S, Yarlagadda N, Awad R, et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. Onco Targets Ther. 2018;11:7095–107.CrossRefGoogle Scholar
  6. 6.
    Braftovi (encorafenib) 50 and 75 mg hard capsules: EU prescribing information. Boulogne-Billancourt: Pierre Fabre Médicament; 2018.Google Scholar
  7. 7.
    Mektovi (binimetinib) 15 mg film-coated tablets: EU prescribing information. Boulogne-Billancourt: Pierre Fabre Médicament; 2018.Google Scholar
  8. 8.
    Braftovi® (encorafenib) capsules: US prescribing information. Boulder: Array BioPharma Inc.; 2018.Google Scholar
  9. 9.
    Mektovi® (binimetinib) tablets: US prescribing information. Boulder: Array BioPharma Inc.; 2018.Google Scholar
  10. 10.
    Shirley M. Encorafenib and binimetinib: first global approvals. Drugs. 2018;78(12):1277–84.CrossRefGoogle Scholar
  11. 11.
    Sullivan RJ, Weber JS, Patel SP, et al. A phase Ib/I2 study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment [abstract no. 9007 + slide presentation]. J Clin Oncol. 2015;33(15 Suppl).Google Scholar
  12. 12.
    Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–15.CrossRefGoogle Scholar
  13. 13.
    Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315–27.CrossRefGoogle Scholar
  14. 14.
    Dummer R, Ascierto PA, Gogas H, et al. Results of COLUMBUS Part 2: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma [abstract no. 1215O + slide presentation]. Ann Oncol. 2017;28(Suppl 5):v429–30.Google Scholar
  15. 15.
    Gogas H, Dummer R, Ascierto PA, et al. Quality-of-life (Qol) in COLUMBUS part 1: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma [abstract no. 1245P + poster]. Ann Oncol. 2017;28(Suppl 5):442.Google Scholar
  16. 16.
    Delord J-P, Robert C, Nyakas M, et al. Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clin Cancer Res. 2017;23(18):5339–48.CrossRefGoogle Scholar
  17. 17.
    Arance A, Dummer R, Ascierto PA, et al. Hospitalization rates in COLUMBUS Part 1: a phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in BRAF-mutant melanoma [abstract no. 1244P + poster]. Ann Oncol. 2017;28(Suppl 5):v441.Google Scholar
  18. 18.
    Tafinlar® (dabrafenib) capsules, for oral use: US prescribing information. East Hanover: Novartis Pharmaceutical Corporation; 2018.Google Scholar
  19. 19.
    Urner-Bloch U, Urner M, Stieger P, et al. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol. 2014;25(7):1437–41.CrossRefGoogle Scholar
  20. 20.
    Dummer R, Keilhoz U. On behalf of the ESMO Guidelines Committee. Appendix 2: cutaneous melanoma (2): eUpdate published online September 2016. Ann Oncol. 2016;27(Suppl 5):v136–7.CrossRefGoogle Scholar
  21. 21.
    Dummer R, Hauschild A, Lindenblatt N, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v126–32.CrossRefGoogle Scholar
  22. 22.
    National Comprehensive Cancer Network®. Clinical practice guidelines in oncology (NCCN Guidelines®): cutaneous melanoma (version 1.2019). Fort Washington: National Comprehensive Cancer Network® Inc.; 2018.Google Scholar
  23. 23.
    Smith AD. NICE OK for Bravtovi skin cancer drug; 2019. http://www.pharmatimes.com/news/nice_ok_for_bravtovi_skin_cancer_drug_1275652. Accessed 22 Jan 2019.
  24. 24.
    Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–9.CrossRefGoogle Scholar
  25. 25.
    Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–88.CrossRefGoogle Scholar
  26. 26.
    Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–60.CrossRefGoogle Scholar
  27. 27.
    Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.CrossRefGoogle Scholar
  28. 28.
    US National Institutes of Health. LGX818 and MEK162 in combination with a third agent (BKM120, LEE011, BGJ398 or INC280) in advanced BRAF melanoma [NCT02159066]. ClinicalTrials.gov; 2019. https://clinicaltrials.gov/ct2/show/NCT02159066. Accessed 22 Jan 2019.
  29. 29.
    US National Institutes of Health. Open label, multicentre study of encorafenib + binimetinib + PD (programmed cell death protein) -1 antibody pembrolizumab (IMMU-TARGET) [NCT02902042]. ClinicalTrials.gov; 2019. https://clinicaltrials.gov/ct2/show/NCT02902042. Accessed 22 Jan 2019.
  30. 30.
    US National Institutes of Health. Sequential combo immuno and target therapy (SECOMBIT) study [NCT02631447]. ClinicalTrials.gov; 2019. https://clinicaltrials.gov/ct2/show/NCT02631447. Accessed 22 Jan 2019.
  31. 31.
    US National Institutes of Health. Immunotherapy with ipilimumab and nivolumab preceded or not by a targeted therapy with encorafenib and binimetinib (EBIN) [NCT03235245]. ClinicalTrials.gov; 2019. https://clinicaltrials.gov/ct2/show/NCT03235245. Accessed 22 Jan 2019.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations